Farol - Maceio, Brazil

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.

Effect of Aromatherapy for Facial Aesthetics in Alleviating Signs of Aging: Pilot Study

STUDY This is a Pilot Study with a Randomized Clinical Trial (RCT) design, using the Consolidated Standards of Reporting Trials (CONSORT) as a reference for reporting the study, in its extension for randomized pilot and feasibility trials, double-blind (researcher and statistician), it was not possible to blind the participants, since the geranium EO (Pelargonium graveolens) has a characteristic aroma. RECRUITMENT Participants will be recruited by disseminating the research at the Institute of Integrated and Oriental Therapy, at the School of Nursing of the University of São Paulo and also by snowballing to employees of other units of the university. Interested parties will access a page containing explanatory text with a summary of the study and a link to fill out the Screening Form, prepared via Google Forms, and referring to the exclusion criteria. For eligible interested parties, an in-person assessment will be scheduled to carry out the topical tolerability test with geranium EO diluted at 1%, in All.me Beauty® Gel Sérum Biocompatível, to be applied to the participant's cubital fossa region, with the aim of to rule out hypersensitivity reactions. After waiting at least 24 hours for the test to take place, excluding immediate and late reactions, a new face-to-face appointment will be scheduled for those who did not manifest any type of adverse reaction, proceeding with the signing of the Terms of Reference. Free and Informed Consent and full completion of the Clinical Assessment Form, prepared electronically using Research Electronic Data Capture - REDCap Brasil and completed by the researcher using electronic equipment such as a cell phone, tablet or notebook. The form includes questions pertinent to facial aesthetic treatments, lifestyle habits, clinical history, non-instrumental facial assessment and instrumental facial assessment. In the latter, the condition of the participant's facial skin will be analyzed, in terms of wrinkles, degree of hydration and elasticity, using the instruments Visioscan® VC 20 Plus (wrinkles), Corneometer® CM 825 and Cutometer® Dual MPA 580 (elasticity). SAMPLE The sample calculation was carried out based on the result obtained by the R2 parameter of the Cutometer® Dual MPA 580 equipment, which is capable of measuring skin elasticity, achieved in the work of Tumsutti et al., 2021, with a similar design and theme. The sample was sized so that an effect size f = 0.7055230 is detected in an ANOVA model for repeated measures with type I and II errors of 5%. Under these conditions, the minimum sample required is 35 participants in total. Estimating a loss of 10% by the end of the intervention, a total of 38 women will be considered, to be distributed between the Placebo Group (G1) and the Intervention Group (G2). STUDY LOCATION All assessments will be carried out by the researcher, in person, in a private office at the Center for Nursing Laboratories in Teaching, Skills, Simulation and Research at School of Nursing of the University of São Paulo. RANDOMIZATION An independent statistician will carry out the randomization using a randomized table, generated by a computer program, and identified by a numerical code. The list with the random numbers and names of the participants will be packed in opaque envelopes, numbered and sealed by a professional external to the investigation. The envelopes will be drawn and opened by a third professional external to the research, who will be responsible for distributing each participant into their randomized group. INTERVENTION G1 will be composed of those whose intervention will only be with the carrier base, the All.me Beauty® Gel Sérum Biocompatível, which serves as a way of diluting the EO and does not interfere with its action and therapeutic process, acting as a placebo. In G2 there will be participants who will receive intervention with geranium EO (Pelargonium graveolens), diluted in All.me Beauty® Gel Sérum Biocompatível, respecting a concentration of 1%, determined based on a work where tolerability was shown in the application of this 1% EO, on oral mucosa, for the treatment of denture stomatitis; For the present study, the sensitivities of the facial skin and smell were taken into account. The intervention with geranium EO (Pelargonium graveolens) will be made available to G1 after the end of the study protocol, in consideration of the ethical precepts of research involving human beings, according to Resolution nº 466/2012. Both the geranium EO (Pelargonium graveolens) and its carrier base must present a report describing its components and, in relation to the EO, its degree of purity. The preparation and dilution will be done in a microbiological testing laboratory at School of Nursing of the University of São Paulo and the formulations will be stored in a round plastic bottle with a screw cap, accompanied by a measuring spoon, also made of plastic. The formulation, which must be stored away from light, humidity and heat, will be distributed to participants for self-application at home, following the Application and Storage Protocol. Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The amount and method of application will be demonstrated at the first meeting and in a video to be prepared by the researcher, which will be sent to the participants. There will be no association with any other technique so that there is no bias in the results obtained. The type and brand of facial soap for routine home use will be evaluated, as well as the photoprotector, requiring the use of formulations that do not contain anti-aging active ingredients for the face and, in relation to the photoprotector, the additional requirement of not presenting pigmentation, which constitutes as an extra layer of protection. To minimize or avoid interference in measurements, assessments will respect a pre-established standard: immediately before each assessment, the participant must clean her face with water and neutral liquid soap, provided by the researcher, and then wait 20 minutes at rest. , for acclimatization in a controlled environment with a thermometer and hygrometer to measure environmental temperature and humidity. Assessments will be carried out during the day, at a fixed time and place, under indirect natural lighting and participants will be instructed to appear without makeup. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, with regard to the item "Instrumental Facial Assessment", before treatment and after four, eight and 12 weeks, according to thematic and similar drawings. At each in-person assessment and, therefore, once a month during the three months of treatment, the participant will be given a vial unit containing 60 grams of the formulation. At the end of the intervention, volunteers must respond to a Final Questionnaire, also made with RedCap, where they will be able to explain their impressions regarding the characteristics and performance of the product, such as odor, consistency and effectiveness, in addition to impressions regarding the appearance of the product. own skin. ASSESSMENT INSTRUMENTS There are several techniques used in RCTs to evaluate the effectiveness of cosmeceutical treatments, with formulations of plant origin or not, in terms of reducing wrinkles and improving skin hydration and elasticity, and most of them have worked with the following instruments, subject to their updates, which will be made available for this study by the company Tecnotests Produtos e Serviços Ltda.: Visioscan® VC 20 Plus - Skin topography: assessment of wrinkles in the upper and middle thirds of the face (forehead, eyelid cheek junction and jowls only on the left side of the face). By digitizing the image obtained by a video sensor, it allows the evaluation of the skin surface, obtaining the following clinical parameters: SEr - skin roughness, determined by the presence of dark spots; SEw - number and width of wrinkles, this value being greater or lesser, according to the number of wrinkles; SEsm - skin softness, with a higher value of this variable being an indication of better skin texture and softness; SEsc - skin peeling. Corneometer® CM 825 - assessment of hydration in the upper and middle thirds of the face (forehead, eyelid cheek junction and jowls only on the left side of the face): its measurement principle is the capacitance of a precision capacitor in a dielectric medium, where changes in the dielectric constant in relation to the variation in hydration of the epidermis, changes the capacitance. The measurement is capable of detecting even the smallest changes in the level of hydration, without being influenced by the deeper layers of the skin, by maintaining its range between 10 and 20 µm from the stratum corneum. Cutometer® Dual MPA 580 - Skin viscoelasticity: assessment of elasticity in the lower third of the face (forehead, eyelid cheek junction and jowls only on the left side of the face). The measuring principle is based on suction created by negative pressure between the instrument and the skin. The depth of skin penetration is determined by an optical system, composed of a light receptor whose intensity varies according to the depth of suction. The resistance that the skin exerts against suction, due to negative pressure, represents its firmness, and its action of returning to the original position, elasticity, both represented in graphs with curves, also presenting several parameters represented by the letters R, F and Q.

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a modular, Phase II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AZD0486 monotherapy administered as an intravenous (IV) infusion in participants with relapsed or refractory B-NHL. The purpose of this study is to determine the efficacy and safety of AZD0486 administered at the RP2D in adults 18 to 80 years of age with relapsed or refractory B-NHL.

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients

SCAD : a Registry of Spontaneous Coronary Artery Dissection

Observational, multicentre, international retrospective and prospective cohort study. Since this is an observational study, a formal sample size is not necessary. At least 500 prospectively recruited patients and 500 historical cases will be enrolled. Patient data will be collected at the following time-points: - First SCAD event visit (retrospectively on chart review) - First follow-up: at time of enrolment - Yearly follow-up: up to 1, 2, 3, 4 and 5 years post enrolment or until study completion Approximately 30 countries and 120 sites will participate in this registry.

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)